Pharma Mar, S.A. (PHMMF)
USD 81.07
(0.0%)
USD 81.07
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 43.36 Million EUR | 1.73% |
| 2022 | 42.63 Million EUR | -13.59% |
| 2021 | 49.33 Million EUR | -12.94% |
| 2020 | 56.66 Million EUR | -34.2% |
| 2019 | 86.11 Million EUR | -7.8% |
| 2018 | 93.4 Million EUR | -6.6% |
| 2017 | 100 Million EUR | 4.73% |
| 2016 | 95.48 Million EUR | 2.02% |
| 2015 | 93.6 Million EUR | 2.33% |
| 2014 | 91.46 Million EUR | -2.97% |
| 2013 | 94.26 Million EUR | -19.26% |
| 2012 | 116.75 Million EUR | -13.99% |
| 2011 | 135.74 Million EUR | -8.4% |
| 2010 | 148.19 Million EUR | 19.05% |
| 2009 | 124.47 Million EUR | 0.0% |
| 2008 | - EUR | -100.0% |
| 2007 | 21.62 Million EUR | -46.88% |
| 2006 | 40.71 Million EUR | 62.89% |
| 2005 | 24.99 Million EUR | -10.46% |
| 2004 | 27.91 Million EUR | -66.92% |
| 2003 | 84.4 Million EUR | 94.12% |
| 2002 | 43.47 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 35.84 Million EUR | -2.3% |
| 2024 Q1 | 40.26 Million EUR | -7.17% |
| 2024 Q2 | 39.38 Million EUR | -2.18% |
| 2023 Q4 | 43.36 Million EUR | -0.48% |
| 2023 Q2 | 43.67 Million EUR | 0.67% |
| 2023 Q3 | 43.57 Million EUR | -0.23% |
| 2023 Q1 | 43.38 Million EUR | 1.78% |
| 2023 FY | 43.36 Million EUR | 1.73% |
| 2022 Q3 | 42.41 Million EUR | -4.94% |
| 2022 Q4 | 42.63 Million EUR | 0.5% |
| 2022 FY | 42.63 Million EUR | -13.59% |
| 2022 Q1 | 47.69 Million EUR | -3.32% |
| 2022 Q2 | 44.62 Million EUR | -6.45% |
| 2021 Q4 | 49.33 Million EUR | -9.49% |
| 2021 FY | 49.33 Million EUR | -12.94% |
| 2021 Q2 | 57.23 Million EUR | 5.23% |
| 2021 Q1 | 54.38 Million EUR | -4.02% |
| 2021 Q3 | 54.5 Million EUR | -4.76% |
| 2020 Q3 | 60.27 Million EUR | -4.09% |
| 2020 Q2 | 62.84 Million EUR | -1.25% |
| 2020 Q1 | 63.63 Million EUR | -26.11% |
| 2020 FY | 56.66 Million EUR | -34.2% |
| 2020 Q4 | 56.66 Million EUR | -5.99% |
| 2019 Q1 | 98.57 Million EUR | 5.54% |
| 2019 Q3 | 89.32 Million EUR | -4.09% |
| 2019 Q4 | 86.11 Million EUR | -3.6% |
| 2019 FY | 86.11 Million EUR | -7.8% |
| 2019 Q2 | 93.13 Million EUR | -5.51% |
| 2018 Q1 | 101.31 Million EUR | 1.32% |
| 2018 Q4 | 93.4 Million EUR | -5.36% |
| 2018 Q3 | 98.7 Million EUR | -10.16% |
| 2018 FY | 93.4 Million EUR | -6.6% |
| 2018 Q2 | 109.86 Million EUR | 8.43% |
| 2017 Q1 | 94.65 Million EUR | -0.87% |
| 2017 FY | 100 Million EUR | 4.73% |
| 2017 Q3 | 98.93 Million EUR | -4.63% |
| 2017 Q2 | 103.73 Million EUR | 9.59% |
| 2017 Q4 | 100 Million EUR | 1.08% |
| 2016 Q4 | 95.48 Million EUR | -4.66% |
| 2016 Q3 | 100.15 Million EUR | -7.18% |
| 2016 FY | 95.48 Million EUR | 2.02% |
| 2016 Q2 | 107.89 Million EUR | 2.6% |
| 2016 Q1 | 105.16 Million EUR | 12.35% |
| 2015 FY | 93.6 Million EUR | 2.33% |
| 2015 Q4 | 93.6 Million EUR | -14.68% |
| 2015 Q1 | 89.44 Million EUR | -2.21% |
| 2015 Q2 | 93.57 Million EUR | 4.61% |
| 2015 Q3 | 109.7 Million EUR | 17.25% |
| 2014 Q3 | 95.38 Million EUR | -3.45% |
| 2014 Q4 | 91.46 Million EUR | -4.11% |
| 2014 Q2 | 98.79 Million EUR | 8.03% |
| 2014 Q1 | 91.45 Million EUR | -2.99% |
| 2014 FY | 91.46 Million EUR | -2.97% |
| 2013 FY | 94.26 Million EUR | -19.26% |
| 2013 Q1 | 114.2 Million EUR | -2.18% |
| 2013 Q2 | 104.6 Million EUR | -8.41% |
| 2013 Q3 | 101.8 Million EUR | -2.68% |
| 2013 Q4 | 94.26 Million EUR | -7.4% |
| 2012 Q3 | 123.55 Million EUR | -2.58% |
| 2012 Q1 | 134.41 Million EUR | -0.98% |
| 2012 FY | 116.75 Million EUR | -13.99% |
| 2012 Q2 | 126.83 Million EUR | -5.64% |
| 2012 Q4 | 116.75 Million EUR | -5.51% |
| 2011 Q4 | 135.74 Million EUR | 56.12% |
| 2011 FY | 135.74 Million EUR | -8.4% |
| 2011 Q3 | 86.94 Million EUR | -38.84% |
| 2011 Q1 | 138.63 Million EUR | -6.45% |
| 2011 Q2 | 142.17 Million EUR | 2.55% |
| 2010 Q4 | 148.19 Million EUR | -0.78% |
| 2010 Q1 | 132.64 Million EUR | 6.56% |
| 2010 Q3 | 149.37 Million EUR | 1.96% |
| 2010 Q2 | 146.49 Million EUR | 10.45% |
| 2010 FY | 148.19 Million EUR | 19.05% |
| 2009 Q2 | 124.14 Million EUR | 0.0% |
| 2009 Q4 | 124.47 Million EUR | 0.0% |
| 2009 FY | 124.47 Million EUR | 0.0% |
| 2009 Q3 | - EUR | -100.0% |
| 2009 Q1 | - EUR | 0.0% |
| 2008 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | -100.0% |
| 2007 FY | 21.62 Million EUR | -46.88% |
| 2006 FY | 40.71 Million EUR | 62.89% |
| 2005 FY | 24.99 Million EUR | -10.46% |
| 2004 FY | 27.91 Million EUR | -66.92% |
| 2003 FY | 84.4 Million EUR | 94.12% |
| 2002 FY | 43.47 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -5.254% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -952.122% |
| SQZ Biotechnologies Company | 27.47 Million USD | -57.868% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 0.012% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -45.691% |
| Mesoblast Limited | 118.7 Million USD | 63.464% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -4473.376% |
| Genus plc | 233.1 Million USD | 81.395% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -1379.941% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -3127.785% |
| Marizyme, Inc. | 18.71 Million USD | -131.698% |
| ContraFect Corporation | 2.88 Million USD | -1405.311% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -5682.4% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -31908.975% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -2898.509% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -1764.524% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -666.442% |
| MultiCell Technologies, Inc. | 202.58 USD | -21407738.878% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 24.563% |
| EV Biologics, Inc. | 1.49 Million USD | -2801.353% |
| Q BioMed Inc. | 4.1 Million USD | -955.187% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -31.017% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -6782.968% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -3430.558% |
| Biomind Labs Inc. | 735.54 Thousand USD | -5796.06% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 74.719% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -233.677% |
| Skye Bioscience, Inc. | 4.61 Million USD | -839.664% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -4783.432% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -30544.865% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -638.67% |
| IMV Inc. | 28.88 Million USD | -50.146% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -168522.419% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -1820.314% |
| GB Sciences, Inc. | 1.75 Million USD | -2365.062% |
| Alpha Cognition Inc. | 1.22 Million USD | -3453.671% |
| HST Global, Inc. | 98.31 Thousand USD | -44009.48% |
| CSL Limited | 12.18 Billion USD | 99.644% |
| Halberd Corporation | 150 Thousand USD | -28812.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -4252.74% |
| Resverlogix Corp. | 6.49 Million USD | -568.125% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -8982.304% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -16867.667% |
| argenx SE | 20 Million USD | -116.84% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 4.811% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1501.061% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -424036.919% |
| Genscript Biotech Corporation | 417.73 Million USD | 89.618% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -21517.418% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -1708.715% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -18813.957% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 35.887% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -1333.089% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -11956.379% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -113.341% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -29073.786% |
| BioStem Technologies, Inc. | 4.71 Million USD | -820.487% |
| ONE Bio Corp. | 19.71 Million USD | -119.974% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -17234.58% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -17336.475% |
| Agentix Corp. | 50 Thousand USD | -86636.0% |
| LadRx Corporation | 33.6 Thousand USD | -128948.384% |
| Cell Source, Inc. | 9.25 Million USD | -368.632% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5634.96% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5634.96% |
| NovAccess Global Inc. | 2.19 Million USD | -1871.38% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -513.165% |
| Itoco Inc. | 228.37 Thousand USD | -18889.653% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -20455.99% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -770.319% |
| Kadimastem Ltd | 891.22 Thousand USD | -4766.106% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -10692.113% |
| CytoDyn Inc. | 30.07 Million USD | -44.195% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -8855.076% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -12225.812% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -454.581% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -35302.449% |
| Rebus Holdings, Inc. | 310 Thousand USD | -13889.677% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -815.848% |
| International Stem Cell Corporation | 4.17 Million USD | -938.009% |
| Bioxytran, Inc. | 1.92 Million USD | -2152.883% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -69385.524% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1888.537% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -421.501% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -405.16% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -2688.08% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -16082.09% |
| Neutra Corp. | 54.15 Thousand USD | -79979.77% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -2269.836% |
| PureTech Health plc | 25.51 Million USD | -69.991% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -3442.483% |
| IXICO plc | 472.02 Thousand USD | -9087.688% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -179.775% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 30.347% |
| CSL Limited | 12.18 Billion USD | 99.644% |
| Cellectis S.A. | 92.77 Million USD | 53.255% |